Trial · NCT03519646
Eliglustat on Gaucher Disease Type IIIB
NCT03519646, Not applicable, Completed, National Taiwan University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Eliglustat on Gaucher Disease Type IIIB. Trials, record NCT03519646. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03519646
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Eliglustat on Gaucher Disease Type IIIB
- NCT number
- NCT03519646
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 4 participants, actual
- Lead sponsor
- National Taiwan University Hospital
- Conditions
- Gaucher Disease, Type III
- Interventions
- Eliglustat
- First posted
- 2018-05-09
- Last updated
- 2022-09-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events | From date of enrollment with information consent form until 24 months or date of death from any cause, whichever came first. | Number of adverse events in patients. |
| Secondary | Assessment of Gaucher related biomarkers test :CCL18 (30% decrease) | Baseline,1,3,6,12,18 and 24 months after receiving Cerdelga. | Measure of Gaucher disease type I biomarkers:CCL18(ng/ml) in plasma. |
| Secondary | Assessment of Gaucher related biomarkers test :Lyso GL1(30% decrease) | Baseline,1,3,6,12,18 and 24 months after receiving Cerdelga. | Measure of Gaucher disease type I biomarkers:Lyso GL1 (ng/mL) in plasma |
| Secondary | Assessment of Gaucher related biomarkers test:Chitotriosidase(30% decrease) | Baseline,1,3,6,12,18 and 24 months after receiving Cerdelga. | Measure of Gaucher disease type I biomarkers:Chitotriosidase(nmol/ml/h) in plasma. |
| Secondary | Change in lymphadenopathy manifestations. | From date of enrollment with information consent form until 24 months or date of death from any cause, whichever came first. | Physician will pay close attention to the lymphadenopathy including size, location, and number of enlarged lymph nodes, evaluate by palpation and radiological (MRI examination). The total size of the lympadenopathy will be combined into one report as "Total size" cm\^3. |
| Secondary | Pharmacokinetics | Plasma concentration-time data will be obtained pre-dose (within 30 minutes prior to dosing) and at 1, 2, 6, 12, 26, 36 hours after 1st dosing, and 1,3,6,12,18 and 24 months thereafter. | Eliglustat plasma concentration over time |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03519646
GET https://conductscience.org/api/trials/v1/NCT03519646/registered